Karyopharm Therapeutics to Highlight Insights from SENTRY Trial in Upcoming Investor Conference Call

Karyopharm's Investor Conference Call: Insights on the SENTRY Trial Results

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a company at the forefront of developing innovative cancer therapies, is set to host a key investor conference call on June 2, 2026. This call will provide expert analysis and discussion following the company’s recent presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting on the Phase 3 SENTRY trial results.

The SENTRY trial explores the efficacy of the combination therapy of selinexor and ruxolitinib in patients with myelofibrosis, a type of blood cancer characterized by the scarring of bone marrow and a host of accompanying symptoms. The call will feature insights from Dr. John Mascarenhas, the principal investigator of the trial, who is also a Professor of Medicine at the Icahn School of Medicine at Mount Sinai. His expertise in blood cancers will provide valuable context for the findings of this pivotal trial.

Conference Call Details

The conference is scheduled to begin at 2:00 PM ET on June 2, 2026. Karyopharm encourages participants to dial in at least ten minutes early to ensure they can join in. Those in the U.S. can access the call by dialing (800) 836-8184, while international participants can call (646) 357-8785. An audio webcast will also be available on the company’s investor relations website, providing an alternative for those who wish to listen in online.

What to Expect from the Call

During the call, Karyopharm's senior management team, alongside Dr. Mascarenhas, will elucidate the SENTRY trial's outcomes, highlighting the potential benefits of selinexor, which acts as a first-in-class inhibitor of exportin 1 (XPO1). The trial is a significant component of Karyopharm’s ongoing mission to develop therapies that target the root causes of cancerous growths.

Selinexor, marketed under the name XPOVIO® in the U.S. and NEXPOVIO® in over 50 countries, is already making waves in the treatment of relapsed or refractory multiple myeloma. The ongoing research into its application for myelofibrosis signifies Karyopharm’s commitment to expanding therapeutic options for patients grappling with challenging forms of cancer.

The importance of this call cannot be understated. By sharing detailed findings from the SENTRY trial, Karyopharm aims to engage investors and stakeholders in understanding the advancements being made in cancer treatment.

Karyopharm's Vision

Karyopharm Therapeutics seeks not only to bring innovative therapies to market but also to impact patient care positively. With a strong base in nuclear export inhibition, the company stands ready to tackle various malignancies, and the SENTRY trial's focus on myelofibrosis is a testament to this commitment.

As Karyopharm continues to innovate within the pharmaceutical landscape, this conference call promises to shed light on key findings that may reshape how myelofibrosis is treated in the future. Investors and interested parties alike are encouraged to tune in for this crucial discussion.

For more information regarding this call and other developments, please visit Karyopharm's official website.